<DOC>
	<DOCNO>NCT00069095</DOCNO>
	<brief_summary>This 4 arm study assess efficacy safety oral capecitabine ( Xeloda ) intravenous ( iv ) fluorouracil/leucovorin , combination iv oxaliplatin ( Eloxatin ) without iv bevacizumab ( Avastin ) , first-line treatment patient metastatic colorectal cancer . Patients randomize receive 1 ) XELOX ( Xeloda 1000 mg/m^2 orally [ po ] twice day [ bid ] Days 1-15 + oxaliplatin 3 week cycle ) , 2 ) FOLFOX-4 ( oxaliplatin + leucovorin + fluorouracil [ 5-FU ] 2 week cycle ) , 3 ) XELOX + bevacizumab ( 7.5 mg iv Day 1 3 week cycle ) , 4 ) FOLFOX-4 + bevacizumab ( 5 mg iv Day 1 2 week cycle ) .</brief_summary>
	<brief_title>A Study Capecitabine ( Xeloda ) Bevacizumab First-line Therapy Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This study conduct 2 part : An initial 2-arm part patient randomize 1 2 different treatment group ( XELOX FOLFOX-4 ) , subsequent 2 x 2 factorial part , add study protocol amendment , additional patient randomize one 4 different treatment group ( XELOX + placebo , FOLFOX-4 + placebo , XELOX + bevacizumab , FOLFOX-4 + bevacizumab ) . Due comparison oral agent capecitabine bolus infused fluorouracil , study blind respect 2 treatment . The study double-blind regard administration bevacizumab , ie , placebo control bevacizumab second part study . The study consist 3 phase , Primary Study Treatment Phase , Post-Study Treatment Phase , Follow-Up Phase . Primary Study Treatment Phase Patients receive 16 cycle ( 2-arm part study ) 24 cycle ( 4-arm part study ) treatment Primary Study Treatment Phase ( 48 week ) . Post-Study Treatment Phase Patients complete 48-week primary study treatment phase without progressive disease eligible enter post-study treatment phase discretion investigator sponsor . Patients enter phase continue treatment regimen initially randomize either progression disease document , unacceptable toxicity occur , patient withdraw consent . Follow-up Phase Patients terminate study treatment primary post-study treatment phase follow disease progression death .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Adult patient ≥ 18 year age . Metastatic colorectal cancer . ≥ 1 target lesion . Previous treatment oxaliplatin bevacizumab . Previous systemic chemotherapy immunotherapy advance metastatic disease . Progressive disease within 6 month completion previous adjuvant therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>